XL092 for Thyroid Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new medicine, XL092, to evaluate its effectiveness for individuals with a type of thyroid cancer that hasn't responded to certain previous treatments and has spread locally or to other parts of the body. XL092 aims to stop cancer cells from growing by blocking signals that prompt them to multiply. The trial may suit those whose thyroid cancer is unresponsive to radioiodine treatment and has spread, and for whom other treatments have failed. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, if you are taking certain anti-retroviral drugs or oral anticoagulants, you may need to change or stop them before starting the trial. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that XL092 is likely to be safe for humans?
Research shows that XL092 is generally safe for people. Studies have found that side effects are mostly mild to moderate, meaning some people might feel uncomfortable, but it's usually not serious. In earlier studies, XL092, both alone and with another drug, proved safe for patients who had already tried several treatments. Importantly, one study confirmed that XL092 was well-tolerated without major safety concerns. This suggests that many people can take XL092 without serious problems.12345
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for thyroid cancer, which often include surgery, radioactive iodine, and traditional chemotherapy, XL092 offers a new approach by targeting specific cancer pathways. XL092 is a small molecule inhibitor that acts on multiple tyrosine kinases, which are enzymes involved in the growth and spread of cancer cells. This mechanism could potentially lead to more effective control of the disease with fewer side effects. Researchers are excited about XL092 because it could provide a more targeted treatment option, reducing the impact on healthy cells and improving patients' quality of life.
What evidence suggests that XL092 might be an effective treatment for thyroid cancer?
Research has shown that XL092 holds promise for treating a type of thyroid cancer unresponsive to standard radioiodine treatment. XL092 is a tyrosine kinase inhibitor, which blocks certain proteins that aid cancer cell growth. In earlier studies, XL092, both alone and with another drug called atezolizumab, produced positive results in patients who had tried other treatments. This trial will focus on XL092 alone, suggesting it might help slow or stop the growth of thyroid cancer cells. Although more research is needed, these early findings offer hope for patients with this type of cancer.23678
Who Is on the Research Team?
Jochen H Lorch
Principal Investigator
Northwestern University
Are You a Good Fit for This Trial?
This trial is for patients with differentiated thyroid cancer that hasn't responded to radioiodine treatment and has spread locally or elsewhere in the body. Participants should have a history of disease progression despite prior therapies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive XL092 orally daily on days 1-21 of each cycle, with cycles repeating every 21 days in the absence of disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up at 30 days then every 3 months for 12 months
What Are the Treatments Tested in This Trial?
Interventions
- XL092
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator